Ziphius

Ziphius is a biopharmaceutical company founded in 2019 and based in New York, with operations in Merelbeke, Belgium. The company specializes in developing self-amplifying RNA (saRNA) vaccines and therapeutics using a proprietary lipid nanoparticle (LNP) delivery platform. Ziphius focuses on addressing infectious diseases, rare genetic disorders, and oncology, with the goal of creating first- and best-in-class RNA medicines. The core innovation of Ziphius is its saRNA-LNP platform, which allows for higher and prolonged protein expression at lower doses, reducing toxicity compared to conventional mRNA. The platform's design supports rapid development and scalable production, making it adaptable for pandemic preparedness. Ziphius is advancing several preclinical programs, including vaccines for Chlamydia Trachomatis and multiple coronavirus strains, as well as a gene therapy for cystic fibrosis. The company has raised $43 million to date and plans to secure additional funding to support its clinical milestones.